182 related articles for article (PubMed ID: 34876018)
1. Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.
Eshraghian A; Moasser E; Azarpira N; Fattahi MR; Nikeghbalian S; Malek-Hosseini SA; Geramizadeh B
BMC Gastroenterol; 2021 Dec; 21(1):458. PubMed ID: 34876018
[TBL] [Abstract][Full Text] [Related]
2. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
[TBL] [Abstract][Full Text] [Related]
3. Characterization of LDLR rs5925 and PCSK9 rs505151 genetic variants frequencies in healthy subjects from northern Chile: Influence on plasma lipid levels.
Rojas C; Ramírez H; Salazar LA; Kalergis AM; Gálvez AS; Escobar-Vera J
J Clin Lab Anal; 2019 Nov; 33(9):e23001. PubMed ID: 31441123
[TBL] [Abstract][Full Text] [Related]
4. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
Di Filippo M; Vokaer B; Seidah NG
J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
[TBL] [Abstract][Full Text] [Related]
5.
Mohamed SH; Hassaan MMM; Ibrahim BA; Sabbah NA
Genet Test Mol Biomarkers; 2021 Sep; 25(9):615-623. PubMed ID: 34550777
[No Abstract] [Full Text] [Related]
6. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
Bing H; Wang W; Li YL
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
[No Abstract] [Full Text] [Related]
8. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis.
Buch S; Sharma A; Ryan E; Datz C; Griffiths WJH; Way M; Buckley TWM; Ryan JD; Stewart S; Wright C; Dongiovanni P; Fracanzani A; Zwerina J; Merle U; Weiss KH; Aigner E; Krones E; Dejaco C; Fischer J; Berg T; Valenti L; Zoller H; McQuillin A; Hampe J; Stickel F; Morgan MY
Aliment Pharmacol Ther; 2021 Apr; 53(7):830-843. PubMed ID: 33565643
[TBL] [Abstract][Full Text] [Related]
9. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
10. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
12. Association study of
Devi K; Bhargave A; Ahmad I; Yadav A; Gupta R
Ann Hum Biol; 2023 Feb; 50(1):56-62. PubMed ID: 36695028
[TBL] [Abstract][Full Text] [Related]
13. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.
Shyamala N; Gundapaneni KK; Galimudi RK; Tupurani MA; Padala C; Puranam K; Kupsal K; Kummari R; Gantala SR; Nallamala KR; Sahu SK; Hanumanth SR
J Gene Med; 2021 Aug; 23(8):e3346. PubMed ID: 33885177
[TBL] [Abstract][Full Text] [Related]
16. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
[TBL] [Abstract][Full Text] [Related]
17. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
18. Liver fat accumulation is associated with circulating PCSK9.
Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
[TBL] [Abstract][Full Text] [Related]
19. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
[TBL] [Abstract][Full Text] [Related]
20. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
